Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | FABP4 | P15090 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.46 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30464235 | 1.00 | FFAR4 (0.50) | FFAR4POLBFABP4LMNATSHR | |
| SCHEMBL26365851 | 0.89 | SLC22A12 (0.45) | FFAR4POLBFABP4LMNATSHR | |
| SCHEMBL31443386 | 0.86 | LMNA (0.49) | FFAR4POLBFABP4LMNATSHR | |
| SCHEMBL1127142 | 0.86 | PDK1 (0.49) | FFAR4POLBLMNATSHRALDH1A1 | |
| SCHEMBL26339156 | 0.86 | BDKRB1 (0.50) | POLBFABP4LMNATSHRALDH1A1 | |
| SCHEMBL14717351 | 0.84 | FABP4 (0.54) | POLBFABP4ALDH1A1SLC40A1BDKRB1 | |
| SCHEMBL1127184 | 0.81 | CYP3A4 (0.52) | FFAR4FABP4LMNATSHRSLC40A1 | |
| SCHEMBL29721254 | 0.81 | CYP3A4 (0.52) | FFAR4FABP4LMNATSHRSLC40A1 | |
| SCHEMBL29721313 | 0.81 | CYP3A4 (0.52) | FFAR4FABP4LMNATSHRSLC40A1 | |
| SCHEMBL30605907 | 0.80 | MCL1 (0.44) | FFAR4POLBFABP4LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121824518-A | Darafil preparation method of nylon | 广州科锐特药业有限公司 | 2026-04-10 | — | — | CN | disclosed |
| EP-4706770-A2 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20240269139-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4397376-A2 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-4159217-B1 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | NOVARTIS AG (CH) | 2024-05-22 | — | — | EP | disclosed |
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2023-09-28 | — | — | US | disclosed |
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2023-09-28 | — | — | US | disclosed |
| EP-4232023-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | Dana-Farber Cancer Institute, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4196228-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | Albert Einstein College of Medicine (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4159217-A1 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2023-04-05 | — | — | EP | disclosed |
| WO-2011047238-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011047238-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-2282636-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2010104899-A1 | THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010104899-A1 | THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | BRAF, RAF1, NRAS | FFAR4 1756/4885POLB 3403/4885FABP4 4231/4885 |
| US-20240269139-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | TTK, MKNK1, MAP3K20 | FFAR4 4518/4885POLB 2538/4885FABP4 4190/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | FFAR4 2855/4885POLB 3156/4885FABP4 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.